P/E ratio for Moderna (MRNA)
P/E ratio as of May 2024 (TTM): -14.1
According to Moderna 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -14.1203. At the end of 2022 the company had a P/E ratio of 8.50.
P/E ratio history for Moderna from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 8.50 | 1.4% |
| 2021 | 8.39 | -115.58% |
| 2020 | -53.9 | 326.73% |
| 2019 | -12.6 | -6.53% |
| 2018 | -13.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.8 | -176.76% | 🇺🇸 USA |
 Novartis NVS | 27.6 | -295.46% | 🇨🇭 Switzerland |
 Merck MRK | 72.3 | -612.12% | 🇺🇸 USA |
 Regulus Therapeutics RGLS | -1.20 | -91.54% | 🇺🇸 USA |
 Dicerna Pharmaceuticals DRNA | N/A | N/A | 🇺🇸 USA |
 Athersys ATHX | -0.0045 | -99.97% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | -35.9 | 153.99% | 🇺🇸 USA |
 Arrowhead Pharmaceuticals
ARWR | -14.7 | 4.31% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.